Gordon JK, et al. - This research was formulated in order to gauge the safety and efficacy of belimumab treatment, in patients with early diffuse cutaneous systemic sclerosis (dcSSc) treated with background mycophenolate mofetil (MMF). Considerable improvements were reported in modified Rodnan skin score (MRSS), among patients in both the treatment groups. It was noted that the median difference was greater in the belimumab group but did not achieve statistical prominence in this small pilot study. Similar adverse events were displayed between the groups. Consistent variations were reported in the gene expression, with the mechanism of action. The data shed light on the connection between the clinical response to belimumab treatment with a notable decrease in pro-fibrotic genes and pathways. In order to investigate the role of belimumab in the treatment of dcSSc, advanced studies were warranted.